Hikma appoints Umang Vohra as a Director

Summary by AI BETAClose X

On 1 December 2026 Hikma will appoint Umang Vohra as an independent Non-Executive Director and as a member of the Audit Committee and Nomination and Governance Committee, bringing prior CEO experience at Cipla and his current Chair/CEO role at Cohance Lifesciences with significant North America and CDMO/generics expertise; the board expects this capability in growth, innovation and portfolio transformation to strengthen strategic oversight and M&A/operational execution, which could positively influence shareholder value; Hikma currently holds BBB/stable ratings from S&P and BBB/stable from Fitch.

Disclaimer*

UK 100

Latest directors dealings